Adocia announced positive topline results from a Phase 1b clinical trial evaluating the dose exposure and dose response relationships of BioChaperone® Combo 75/25 at three different doses in people with type 2 diabetes. BioChaperone Combo is a proprietary formulation combining basal insulin glargine (active ingredient in Lantus®, Sanofi and Basaglar®, Eli Lilly) and prandial insulin lispro (active ingredient in Humalog®, Eli Lilly and Admelog®, Sanofi). BioChaperone® technology enables this combination by solubilizing insulin glargine at neutral pH, where it is compatible with fast-acting insulin analogs. This study aimed to document the dose exposure relationship of BioChaperone Combo in people with type 2 diabetes. In the double-blinded, randomized, four period crossover trial, using automated 30-hour euglycemic clamp, 32 participants with type 2 diabetes mellitus were randomly allocated to a sequence of four treatments, that is one of three single doses of BioChaperone Combo 75/25 (0.6 U/kg; 0.8 U/kg or 1.0 U/kg) or one single dose of Humalog® Mix25TM at 0.8 U/kg. The primary endpoints were the assessments of dose-proportionality for total insulin exposure (AUCtotal_insulin0-last) and maximal observed total plasma insulin concentration (Cmax) across three doses of BioChaperone Combo.Both primary endpoints were met (AUC0-last overall dose exposure slope 0.93; 95% confidence interval [0.58; 1.29]; Cmax overall dose exposure slope 0.80, 95% CI [0.43; 1.17]), and a dose-proportionality relationship was demonstrated for all exposure pharmacokinetic parameters assessed in the early, intermediate and basal phases. Secondary endpoints included documentation of the dose-response relationship for the total metabolic effect (glucose infusion rate: GIR) and the comparison of the pharmacodynamic and pharmacokinetic profiles of BioChaperone Combo (0.8 U/kg) with those of Humalog Mix25TM (0.8 U/kg). Dose-response linearity was established for the metabolic response across all three doses for all parameters assessed. Additionally, at 0.8 U/kg, BioChaperone Combo displayed a statistically faster early metabolic effect (AUCGIR 0-2h, p=0.0020), a statistically lower late-prandial effect (AUCGIR 3-6h, p=0.0007) and a statistically stronger late basal effect (AUCGIR 24-30h, p=0.0027) than HumalogMix. The overall metabolic effect was similar for both treatments (AUCGIR 0-30h, NS). These results were in line with pharmacokinetics and confirmed previously obtained results in people with type 2 diabetes. All treatments were well tolerated. No new or unexpected safety findings were reported and no local reactions were seen on the site of administration for any treatment.